Kuijf Mark L, Geleijns Karin, Ennaji Noureddine, van Rijs Wouter, van Doorn Pieter A, Jacobs Bart C
Department of Neurology, Erasmus MC, 's-Gravendijkwal 230, 3015CE, Rotterdam, The Netherlands.
J Neuroimmunol. 2008 Dec 15;205(1-2):110-2. doi: 10.1016/j.jneuroim.2008.08.013. Epub 2008 Oct 5.
Immune responses to microbial glycolipids that cross-react to neural epitopes may trigger the Guillain-Barré syndrome (GBS). CD1 molecules are involved in antigen presentation of glycolipids and variation in CD1 genes was recently reported to confer susceptibility to develop GBS. This hypothesis was tested by comparing single nucleotide polymorphisms (SNPs) of CD1A and CD1E in 312 well defined GBS patients and 212 healthy controls. SNPs in CD1A and CD1E were not associated with GBS susceptibility, specific clinical subgroups, anti-ganglioside antibodies, antecedent infections and prognosis. Based on this study, CD1 polymorphisms are not a susceptibility or disease modifying factor in GBS.
对与神经表位发生交叉反应的微生物糖脂的免疫反应可能会引发吉兰-巴雷综合征（GBS）。CD1分子参与糖脂的抗原呈递，最近有报道称CD1基因的变异会使人易患GBS。通过比较312例明确诊断的GBS患者和212名健康对照者的CD1A和CD1E单核苷酸多态性（SNP）来验证这一假设。CD1A和CD1E中的SNP与GBS易感性、特定临床亚组、抗神经节苷脂抗体、前驱感染及预后均无关联。基于本研究，CD1多态性不是GBS的易感性或疾病修饰因素。
